Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Acid
Conditions
Gastric Acid, Human Experimentation
Trial Timeline
May 1, 2008 → Aug 1, 2008
NCT ID
NCT00765206About Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent)
Omeprazole/sodium bicarbonate + omeprazole magnesium (20 mg equivalent) is a phase 3 stage product being developed by Bayer for Gastric Acid. The current trial status is completed. This product is registered under clinical trial identifier NCT00765206. Target conditions include Gastric Acid, Human Experimentation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00765206 | Phase 3 | Completed |
Competing Products
20 competing products in Gastric Acid